

IN THE CLAIMS:

Please amend the claims as follows:

1. (Previously Presented) A purified antibody, or a functional fragment thereof, wherein said antibody or functional fragment specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells, and comprises a sequence at least 85% identical to the amino acid sequence of SEQ ID NO:1 and a sequence at least 85% identical to the amino acid sequence of SEQ ID NO:3.
2. (Previously Presented) The antibody or functional fragment of claim 1, wherein said antibody or functional fragment inhibits cell proliferation of CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), or COLO-206F (DSMZ Accession No. ACC 21) cells.
3. (Cancelled)
4. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment induces apoptosis of at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells.
5. (Cancelled).
6. (Cancelled).
7. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:1.
8. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:3.
9. (Currently Amended) A purified antibody, or functional fragment thereof, wherein said antibody or functional fragment comprises the amino acid sequence of SEQ ID NO:1 and specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC

169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells.

10. (Currently Amended) A purified antibody, or functional fragment thereof, wherein said antibody or functional fragment comprises the amino acid sequence of SEQ ID NO:3 and specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells.

11. (Currently Amended) ~~A purified antibody, or functional fragment thereof,~~ The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises the amino acid sequence of SEQ ID NOS:1 and 3 and specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells.

12. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment is a human antibody.

13. (Previously Presented) The purified antibody of claim 1, wherein said antibody is a monoclonal antibody.

14. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said functional fragment that specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells is selected from the group consisting of Fv, Fab, Fab', and F(ab')₂.

15. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said functional fragment that specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells

comprises a fragment that is at least 90% identical to the sequence of SEQ ID NO:1 or SEQ ID NO:3.

16. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said functional fragment that specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells comprises a fragment of the sequence of SEQ ID NO: 1 or SEQ ID NO:3.

17.-53. (Canceled)

54. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1 and a sequence at least at least 90% identical to the amino acid sequence of SEQ ID NO:3.

55. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1 and a sequence at least at least 95% identical to the amino acid sequence of SEQ ID NO:3.

56. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1 and a sequence at least at least 95% identical to the amino acid sequence of SEQ ID NO:3.

57. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a sequence that is at least 85% identical to 100 contiguous amino acids of SEQ ID NO:1.

58. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a sequence that is at least 85% identical to 100 contiguous amino acids of SEQ ID NO:3.

59. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a sequence that is at least 90% identical to 100 contiguous amino acids of SEQ ID NO:1.

60. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a sequence that is at least 90% identical to 100 contiguous amino acids of SEQ ID NO:3.

61. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a sequence that is at least 95% identical to 100 contiguous amino acids of SEQ ID NO:1.

62. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a sequence that is at least 95% identical to 100 contiguous amino acids of SEQ ID NO:3.

63. (Previously Presented) A purified antibody, or a functional fragment thereof that specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells, wherein the antibody comprises SEQ ID NO:1 and SEQ ID NO:3 with a conservative amino acid substitution in either SEQ ID NO:1 or SEQ ID NO:3.

64. (Previously Presented) A purified polypeptide comprising the amino acid sequence of SEQ ID NO:1.

65. (Previously Presented) A purified polypeptide comprising the amino acid sequence of SEQ ID NO:3.